Philip L. De Jager, MD, PhD

  • Weil-Granat Professor of Neurology (in the Taub Institute for Research on Alzheimer’s Disease and the aging Brain)
  • Director, Center for Translational and Computational Neuroimmunology
  • Director, Multiple Sclerosis Center
Philip L. De Jager, MD, PhD

Dr. Philip L. De Jager is professor of neurology (in the Taub Institute for Research on Alzheimer's disease and the Aging Brain and the Columbia Precision Medicine Initiative). After graduating from Yale University with a degree in Molecular Biophysics & Biochemistry, Dr. De Jager received a PhD in Neurogenetics from Rockefeller University and an MD from Cornell University Medical College, before completing his MMSc in Clinical Investigation at Harvard Medical School (HMS) and MIT. He served as a neurology resident in the Partners Neurology Residency Program at the Massachusetts General Hospital and Brigham and Women’s Hospital. He then joined the faculty at HMS, rising to the rank of associate professor before joining CUMC.

The goal of Dr. De Jager's work as a clinician-scientist is to apply modern methods of neuro-immunology, statistical genetics, and systems biology to the understanding of common neurodegenerative diseases. At CUIMC, Dr. De Jager serves as chief of the Department of Neurology's Division of Neuroimmunology, which focuses on characterizing and targeting the neuro-immunologic component of neurodegenerative disease. Dr. De Jager will also serve as director of a new Center for Translational & Computational Neuro-Immunology, and will also direct the Columbia University Multiple Sclerosis Center. 

Departmental Appointments

  • Department of Neurology
    Division of Neuroimmunology

Education & Training

  • MD, Cornell University Medical College
  • Internship: Beth Israel Deaconess Medical Center
  • Residency: Brigham & Women's Hospital/Massachusetts General Hospital
  • Fellowship: Brigham & Women's Hospital

NIH Grants

  • BIOGEN/COLUMBIA COLLABORATION ON CHARACTERIZING AGING SINGLE MICROGLIA: A REFERENCE ATLAS FOR ALZHEIMER?S DISEASE (P&S Industry Clinical Trial)

    Aug 13 2019 - Aug 13 2024

    TYSABRI EXTENDED INTERVAL DOSING (P&S Industry Clinical Trial)

    Feb 13 2019 - Feb 13 2024

    MOLECULAR CHARACTERIZATION OF THE ROLE OF MICROGLIA IN ALZHEIMER''S DISEASE. (P&S Industry Clinical Trial)

    Nov 29 2018 - Nov 29 2023

    MULTI-OMIC NETWORK-DIRECTED PROTEOFORM DISCOVERY, DISSECTION AND FUNCTIONAL VALIDATION TO PRIORITIZE NOVEL AD THERAPEUTIC TARGETS (Federal Gov)

    Sep 30 2018 - Aug 31 2023

    CHILD MALTREATMENT AND RISK FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER S DISEASE (Federal Gov)

    Sep 1 2018 - May 31 2023

    CONVERGENCE OF MYELOID SUSCEPTIBILITY PROTEIN FUNCTION IN ALZHEIMER S DISEASE (Federal Gov)

    Apr 15 2018 - Mar 31 2023

    CREATION OF A REFERENCE MAP OF SINGLE CELL TRANSCRIPTOMES OF CLINICALLY AND NEUROPATHOLOGICALLY WELL CHARACTERIZED AGING HUMAN FRONTAL CORTEX AND WHITE MATTER (P&S Industry Clinical Trial)

    Mar 6 2018 - Mar 6 2023

    IDENTIFYING THE MOLECULAR SYSTEMS, NETWORKS, AND KEY MOLECULES THAT UNDERLIE COGNITIVE RESILIENCE (Federal Gov)

    Sep 15 2017 - May 31 2022

    ALTERED CD4+ T CELL FUNCTION IN RELATION TO THE AHI1 MS LOCUS (Federal Gov)

    Mar 1 2018 - Mar 31 2022

    CREATING AND DEPLOYING A TOOLKIT FOR HUMAN MICROGLIA IN NEURODEGENERATION (Private)

    Dec 1 2018 - Nov 30 2021

    PATHWAY DISCOVERY, VALIDATION AND COMPOUND IDENTIFICATION FOR ALZHEIMER S DISEASE (Federal Gov)

    Sep 20 2013 - Aug 31 2020

    DECONSTRUCTING AND MODELING THE SINGLE CELL ARCHITECTURE OF THE ALZHEIMER BRAIN (Federal Gov)

    Sep 15 2017 - Jun 30 2020

    ALZHEIMER S DISEASE RESEARCH CENTER - OVERALL (Federal Gov)

    Jun 15 2015 - May 31 2020

    IDENTIFYING, VALIDATING AND TARGETING AD SUSCEPTIBILITY NETWORKS IN MONOCYTES (Federal Gov)

    May 1 2018 - Apr 30 2020

    NATIONAL MULTIPLE SCLEROSIS TISSUE REPOSITORY NETWORK (Private)

    Jan 1 2019 - Jun 30 2019

    GINGER PROGRAM TRAINING AND TEACHING - DAN FELSKY (Private)

    Jul 1 2018 - Jun 30 2019

    INFLUENCE OF GENOTYPE ON MICROGLIA PHENOTYPE AND FUNCTION IN PD (Federal Gov)

    Jul 1 2017 - Jun 30 2019

    TEMPORAL TRENDS, NOVEL IMAGING AND MOLECULAR CHARACTERIZATION OF PRECLINICAL AND CLINICAL ALZHEIMER S DISEASE IN THE FRAMINGHAM COHORTS (Federal Gov)

    Aug 15 2018 - May 31 2019

    MONOCYTE TRANSCRIPTOMIC RNASEQ DATA AND SERUM METABOLOMIC ANALYSES IN ROSMAP (Private)

    Jan 1 2017 - Dec 31 2018

    GENETICS, FUNCTION AND SMALL MOLECULES: TARGETING THE CD33 AD LOCUS (Private)

    Jul 1 2017 - Aug 31 2018

    RISK FACTORS, PATHOLOGY AND CLINICAL EXPRESSIONS OF AD (Federal Gov)

    Jul 1 2017 - Jun 30 2018

    EXPLORING THE ROLE OF THE BRAIN EPIGENOME: COGNITIVE DECLINE AND LIFE EXPERIENCE (Federal Gov)

    Jul 1 2017 - Jun 30 2018

    AFRICAN ANCESTRY AND THE GENOMIC ARCHITECTURE OF AD AND OTHER COMMON NEURODEGENERATIVE DISEASE NEUROPATHOLOGIES (Federal Gov)

    Jun 1 2017 - May 31 2018

    TAU-SLICEOSOME INTERACTIONS IN ALZHEIMER S DISEASE (Federal Gov)

    Jun 1 2017 - Apr 30 2018

    INTEGRATING RISK FACTORS AND BIOMARKERS FOR PREDICTION IN PRESYMPTOMATIC MS (Private)

    Aug 7 2017 - Mar 31 2018

    GENETIC AND EPIGENETIC MECHANISMS OF RESIDUAL COGNITION: A TRANSLATIONAL STUDY OF RESILIENCE IN ALZHEIMER S DISEASE AND AGING (Private)

    May 1 2017 - Mar 31 2018

    RISK FACTORS, PATHOLOGY AND CLINICAL EXPRESSIONS OF AD (Federal Gov)

    Jul 1 2017 - Jul 2 2017